Two Seas Capital LP bought a new position in shares of Lucid Diagnostics Inc. (NASDAQ:LUCD – Free Report) during the second quarter, Holdings Channel.com reports. The fund bought 6,000,000 shares of the company’s stock, valued at approximately $6,420,000.
Several other institutional investors and hedge funds have also made changes to their positions in the company. Bank of America Corp DE boosted its position in shares of Lucid Diagnostics by 41.5% in the 3rd quarter. Bank of America Corp DE now owns 40,663 shares of the company’s stock valued at $41,000 after purchasing an additional 11,917 shares during the period. Pine Valley Investments Ltd Liability Co lifted its stake in Lucid Diagnostics by 73.2% in the first quarter. Pine Valley Investments Ltd Liability Co now owns 34,283 shares of the company’s stock valued at $39,000 after buying an additional 14,487 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Lucid Diagnostics by 35.7% in the first quarter. Goldman Sachs Group Inc. now owns 86,302 shares of the company’s stock valued at $129,000 after buying an additional 22,727 shares during the last quarter. Centiva Capital LP acquired a new stake in shares of Lucid Diagnostics in the third quarter valued at approximately $25,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of Lucid Diagnostics in the first quarter valued at approximately $39,000. 74.01% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of equities analysts have recently commented on the stock. Maxim Group cut their target price on shares of Lucid Diagnostics from $3.00 to $2.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Ascendiant Capital Markets increased their price target on shares of Lucid Diagnostics from $9.00 to $9.25 and gave the stock a “buy” rating in a research note on Monday, June 8th. Weiss Ratings downgraded shares of Lucid Diagnostics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday. BTIG Research restated a “buy” rating and issued a $2.50 price objective on shares of Lucid Diagnostics in a research note on Monday, August 17th. Finally, Wall Street Zen lowered shares of Lucid Diagnostics from a “hold” rating to a “sell” rating in a research note on Saturday, July 4th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $4.19.
Lucid Diagnostics Price Performance
NASDAQ:LUCD opened at $0.96 on Friday. The firm has a market cap of $195.98 million, a price-to-earnings ratio of -2.05 and a beta of 1.08. The firm’s fifty day moving average price is $0.99 and its 200 day moving average price is $1.12. Lucid Diagnostics Inc. has a 1-year low of $0.86 and a 1-year high of $1.63.
Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.06) EPS for the quarter, hitting analysts’ consensus estimates of ($0.06). The firm had revenue of $1.47 million for the quarter, compared to analysts’ expectations of $1.43 million. As a group, analysts expect that Lucid Diagnostics Inc. will post -0.23 earnings per share for the current fiscal year.
Lucid Diagnostics Profile
Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.
Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.
See Also
- Five stocks we like better than Lucid Diagnostics
- 2 Biotech Stocks Shaping Up for Major Breakouts
- 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
- 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run
- Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?
Want to see what other hedge funds are holding LUCD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lucid Diagnostics Inc. (NASDAQ:LUCD – Free Report).
Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
